Literature DB >> 1131831

Pharmacological and therapeutic efficacy of daunomycin:DNA complex in mice.

T Ohnuma, J F Holland, J H Chen.   

Abstract

The pharmacological and therapeutic effects of the daunomycin (DNM):DNA complex were compared with those of free DNM in mice. A complex formation between dnm and DNA (1:11.7, w/w) resulted in a 79% decrease in DNM complex was dialyzable. The DNM fluorescence was completely recovered from the complex in 0.3 N HCl and 50% ethanol solution, and a short contact with biological tissues studied did not quench DNM fluorescence after extraction. The plasma fluorescence (DNM equivalent) 5 min after the i.v. injection of DNM:DNA complex at a dose of 20 mg/kg was 60-fold higher than that of an equivalent amount of free DNM. The complex was cleared for plasma with an initial half-life of 20 min. In spite of an initally higher blood generally similar except in liver and spleen, where DNM equivalent were significantly higher than those of free DNM. The uptake of DNM:DNA into L1210 cells in vitro was low and, at 1 hr, was about one-twentieth of that from DNM. Treatment of DBA/2 mice bearing i.p. L1210 leukemia transplant (initial cell number, 10-3) with DNM:DNA complex resulted in identical increases in life-span as occurred with free DNM. When routes of cell transplant and treatment were different, no therapeutic advantage of DNM:DNA over DNM was seen.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1131831

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

2.  Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors:  M Beran; B Andersson; S Eksborg; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.

Authors:  B Andersson; I Andersson; M Beran; H Ehrsson; S Eksborg
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography.

Authors:  B Andersson; M Beran; B Eberhardsson; S Eksborg; P Slanina
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.

Authors:  Na Zhao; Qixin Leng; Martin C Woodle; A James Mixson
Journal:  Biochem Biophys Res Commun       Date:  2019-04-04       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.